GHK-Cu | BioAvailable

The verdict

Our read at a glance.

Whether GHK-Cu claims stay limited to narrow topical dermatology and wound-biology contexts instead of expanding into unsupported systemic anti-aging, recovery, hair-growth, disease-treatment, or longevity claims.

The signal: Topical GHK-Cu has limited human cosmetic and wound evidence, mostly old, narrow, small, or formulation-specific. The post-laser topical RCT did not show significant objective added benefit, though satisfaction differed. Mechanistic, animal, ex vivo, gene-expression, delivery, and formulation studies are plausibility/context evidence, not clinical proof.
The unknown: Whether any well-characterized GHK-Cu product can show clinically meaningful human outcomes in controlled studies, and how much product form, purity, delivery context, endpoint choice, and formulation identity change interpretation.
Our read: Context-dependent and source-sensitive: the expanded record can explain why some topical skin claims are plausible but limited, while systemic regeneration, injection-style, disease-treatment, hair-regrowth, and longevity claims remain unsupported by direct human GHK-Cu evidence.

The explainer

Watch the 46:57 explainer.

8.1K views · May 2026

The mechanism

How it works.

GHK-Cu is a small three-amino-acid peptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. The proposed mechanism is that it delivers copper into skin and connective tissue and shifts the local repair program, turning on genes tied to collagen and extracellular-matrix turnover and influencing inflammatory tone and new blood-vessel formation. Most of this comes from cell-culture, animal, and gene-expression work plus limited topical human studies, and it has not been shown to produce systemic regenerative effects in people.

Safety & regulatory boundary

The consequential part.

GHK, GHK-Cu, copper tripeptide-1, prezatide copper, acetate forms, analogs, cosmetic blends, devices, compounded products, and internet-market products are not interchangeable. Non-injectable GHK-Cu is under 503A Category 1 evaluation as of the FDA May 14, 2026 PDF; injectable-route GHK-Cu is on FDA safety-risk materials with immunogenicity/aggregation/impurity and limited-human-data concerns. These FDA materials are not approval, ban, efficacy, or safety determinations.

What's next

What we're watching.

Controlled topical human outcome trials, posted results from registry records, clearer product characterization, and FDA updates that distinguish non-injectable 503A evaluation from injectable-route safety-risk concerns.

Context

Why this is discussed.

It gets attention because copper-peptide skin-repair narratives are common in cosmetics and internet peptide culture, while the public evidence mixes old human topical studies, registry records, laboratory biology, formulation work, and regulatory cautions.

The evidence base

54 cited references.

Regulatory & labels10

FDA GSRS: Prezatide copper, UNII 6BJQ43T1I9

FDA Global Substance Registration System · Current database page

FDA 503A bulks list: GHK-Cu Category 1 status

U.S. Food and Drug Administration · Updated 2026-05-14

Certain bulk drug substances for use in compounding that may present significant safety risks